A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).

Cisplatin-based combination chemotherapy is frequently used to treat patients with carcinoma of unknown primary site (CUPS). Response rates in the literature range from 12% to 26% and median survival from 5 to 7 months. The goal of this study was to evaluate the combination of carboplatin and prolon...

Descripción completa

Detalles Bibliográficos
Autores principales: Warner, E., Goel, R., Chang, J., Chow, W., Verma, S., Dancey, J., Franssen, E., Dulude, H., Girouard, M., Correia, J., Gallant, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150411/
https://www.ncbi.nlm.nih.gov/pubmed/9649162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150411/
https://www.ncbi.nlm.nih.gov/pubmed/9649162

Ejemplares similares